Barbara Muz

4.0k total citations · 1 hit paper
58 papers, 2.8k citations indexed

About

Barbara Muz is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Barbara Muz has authored 58 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 23 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Barbara Muz's work include Multiple Myeloma Research and Treatments (23 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Protein Degradation and Inhibitors (6 papers). Barbara Muz is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Protein Degradation and Inhibitors (6 papers). Barbara Muz collaborates with scholars based in United States, Egypt and United Kingdom. Barbara Muz's co-authors include Abdel Kareem Azab, Pilar de la Puente, Feda Azab, Micah John Luderer, Ewa Paleolog, Ravi Vij, Serafim Kiriakidis, Jennifer Sun, Justin King and Kinan Alhallak and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Biomaterials.

In The Last Decade

Barbara Muz

56 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy

2015 1.5k citations Barbara Muz, Pilar de la Puente et al. profile →

Peers

Countries citing papers authored by Barbara Muz

Since Specialization

Citations

This map shows the geographic impact of Barbara Muz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Muz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Muz more than expected).

Fields of papers citing papers by Barbara Muz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Muz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Muz. The network helps show where Barbara Muz may publish in the future.

Co-authorship network of co-authors of Barbara Muz

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Muz. A scholar is included among the top collaborators of Barbara Muz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Muz. Barbara Muz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 6418: xWU-NK-101 as salvage therapy post immune checkpoint blockade (ICB) 2023 ·Cancer Research ·(unknown), Barbara Muz, (unknown), (unknown), Xiaohua Li, Gregory S. Watson, (unknown), (unknown), Melissa M. Berrien-Elliott, (unknown), Sergio Rutella, Matthew Cooper, (unknown), Jan Davidson‐Moncada	0
2	An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma 2022 ·Cell Death and Disease ·(unknown), Barbara Muz, (unknown), (unknown), (unknown), Karin Goldberg, (unknown), Miriam Shmuel, (unknown), (unknown), Hadas Pahima, (unknown), Marc S. Raab, Alexandra M. Poos, Niels Weinhold, Chaggai Rosenbluh, Moshe E. Gatt, Wilhelm Palm, Abdel Kareem Azab, Boaz Tirosh	4
3	Synthesis, equilibrium, and biological study of a C-7 glucose boronic acid derivative as a potential candidate for boron neutron capture therapy 2022 ·Bioorganic & Medicinal Chemistry ·Barbara Muz, Abdel Kareem Azab, (unknown), Erika Del Grosso, Silvia Fallarini, Daniela Imperio, Luigi Panza	9
4	Targeting E-selectin to Tackle Cancer Using Uproleselan 2021 ·Cancers ·Barbara Muz, (unknown), (unknown), (unknown), (unknown), Noha N. Salama, Abdel Kareem Azab	40
5	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy 2021 ·Leukemia ·Kinan Alhallak, Jennifer Sun, (unknown), (unknown), Julie O’Neal, Barbara Muz, Justin King, Daniel Kohnen, Ravi Vij, Samuel Achilefu, John F. DiPersio, Abdel Kareem Azab	45
6	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma 2021 ·Scientific Reports ·Kinan Alhallak, (unknown), Pilar de la Puente, Jennifer Sun, Mark A. Fiala, Feda Azab, Barbara Muz, İlyas Şahin, Ravi Vij, John F. DiPersio, Abdel Kareem Azab	6
7	Nanoparticle T cell engagers for the treatment of acute myeloid leukemia 2021 ·Oncotarget ·Kinan Alhallak, Jennifer Sun, Barbara Muz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Samuel Achilefu, John F. DiPersio, Abdel Kareem Azab	6
8	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma 2020 ·Cancers ·Jennifer Sun, Barbara Muz, Kinan Alhallak, (unknown), (unknown), Zhe Wang, (unknown), (unknown), Mark A. Fiala, Justin King, Daniel Kohnen, Noha N. Salama, Ravi Vij, Abdel Kareem Azab	66
9	Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Cinzia Federico, Jennifer Sun, Barbara Muz, Kinan Alhallak, Pippa F. Cosper, Naoshad Muhammad, (unknown), (unknown), Stephanie Markovina, Perry W. Grigsby, Julie K. Schwarz, Abdel Kareem Azab	48
10	Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy 2019 ·Pharmaceutical Research ·Micah John Luderer, Barbara Muz, Kinan Alhallak, Jennifer Sun, (unknown), (unknown), Pilar de la Puente, Cinzia Federico, Abdel Kareem Azab	30
11	Targeting CD47 As a Novel Therapeutic Strategy in Multiple Myeloma 2017 ·Blood ·Barbara Muz, (unknown), Justin King, Daniel Kohnen, Mark A. Fiala, Ravi Vij, Ben Capoccia, Pamela T. Manning, Noha N. Salama, Abdel Kareem Azab	2
12	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma 2017 ·Journal of Controlled Release ·Pilar de la Puente, Micah John Luderer, Cinzia Federico, (unknown), Rebecca C. Gilson, Christopher Egbulefu, Kinan Alhallak, Shruti Shah, Barbara Muz, Jennifer Sun, Justin King, Daniel Kohnen, Noha N. Salama, Samuel Achilefu, Ravi Vij, Abdel Kareem Azab	58
13	Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma 2017 ·Translational Oncology ·Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab	26
14	Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors 2017 ·Journal of Pharmaceutical Sciences ·Pilar de la Puente, Nicole Fettig, Micah John Luderer, (unknown), Shruti Shah, Barbara Muz, Vaishali Kapoor, Sreekrishna Goddu, Noha N. Salama, Christina Tsien, Dinesh Thotala, Kooresh I. Shoghi, Buck E. Rogers, Abdel Kareem Azab	49
15	Spotlight on ixazomib: potential in the treatment of multiple myeloma 2016 ·Drug Design Development and Therapy ·Abdel Kareem Azab, Barbara Muz, (unknown), (unknown), Micah John Luderer, (unknown)	102
16	Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma 2015 ·Leukemia & lymphoma ·Pilar de la Puente, Feda Azab, Barbara Muz, Micah John Luderer, Jack L. Arbiser, Abdel Kareem Azab	18
17	3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma 2015 ·Biomaterials ·Pilar de la Puente, Barbara Muz, Rebecca C. Gilson, Feda Azab, Micah John Luderer, Justin King, Samuel Achilefu, Ravi Vij, Abdel Kareem Azab	103
18	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia 2015 ·Leukemia Research ·Pilar de la Puente, Ellen Weisberg, Barbara Muz, Atsushi Nonami, Micah John Luderer, Richard M. Stone, Junia V. Melo, James D. Griffin, Abdel Kareem Azab	19
19	Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia 2014 ·Molecular Cancer Research ·Barbara Muz, Pilar de la Puente, Feda Azab, Irene M. Ghobrial, Abdel Kareem Azab	26
20	The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting 2014 ·Laboratory Investigation ·Zhi Hong Lu, Sergey A. Kaliberov, Jingzhu Zhang, Barbara Muz, Abdel Kareem Azab, Rebecca Sohn, Lyudmila N. Kaliberova, (unknown), David T. Curiel, Jeffrey M. Arbeit	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact